Search Result

Results for "

ICI

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Adrenergic Receptor (16) Aldose Reductase (2) Angiotensin Receptor (2) Antifolate (1) Apoptosis (18) Autophagy (11) Bcl-2 Family (2) Bombesin Receptor (3) Caspase (2) Cholecystokinin Receptor (2) COX (1) Dopamine Receptor (3) Drug Derivative (5) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (3) Elastase (2) Endogenous Metabolite (2) Environmental Pollutants (1) Estrogen Receptor/ERR (13) GABA Receptor (2) GnRH Receptor (5) HCN Channel (2) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (3) HSP (8) Isotope-Labeled Compounds (16) Leukotriene Receptor (6) Lipoxygenase (2) Nucleoside Antimetabolite/Analog (2) Opioid Receptor (6) p38 MAPK (1) Parasite (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (4) Potassium Channel (1) Prostaglandin Receptor (6) Reference Standards (13) Sodium Channel (1) Thymidylate Synthase (3) TNF Receptor (1)
By Research Areas:	Cancer (32) Cardiovascular Disease (18) Endocrinology (18) Infection (3) Inflammation/Immunology (19) Metabolic Disease (12) Neurological Disease (35)
Click Chemistry:	Alkynes (1)

101

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13757A

Tamoxifen Maximum Cited Publications 229 Publications Verification ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757) .

HY-13636

Fulvestrant 130+ Cited Publications ICI 182780; ZD 9238; ZM 182780	Estrogen Receptor/ERR Autophagy Apoptosis	Inflammation/Immunology Cancer
Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-13951

Zenidolol hydrochloride 40+ Cited Publications ICI-118551 hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Zenidolol (ICI-118551) hydrochloride is a highly selective β2 adrenergic receptor antagonist, with K_is of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.

HY-13757

Tamoxifen Citrate Maximum Cited Publications 229 Publications Verification ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Infection Neurological Disease Inflammation/Immunology Cancer
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice .

HY-10821

Raltitrexed 10+ Cited Publications ZD1694; D1694; ICI-D1694	Thymidylate Synthase Nucleoside Antimetabolite/Analog	Cancer
Raltitrexed is an antimetabolite agent used in chemotherapy, acting by inhibiting thymidylate synthase.

HY-17492

Zafirlukast 3 Publications Verification ICI 204219	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-100543

Zenidolol 40+ Cited Publications ICI-118551	Adrenergic Receptor Apoptosis Caspase Bcl-2 Family HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Zenidolol (ICI-118551) is a selective β2-adrenergic receptor antagonist with K_i values of Zenidolol for β2, β1 and β3 adrenergic receptors of 0.7, 49.5 and 611 nM, respectively. Zenidolol exerts antitumor effects via inducing apoptosis, inhibiting tumor sphere formation, and downregulating the HIF pathway by blocking β2-AR on tumor cells. Zenidolol exhibits a unique pulmonary vessel-specific vasodilatory effect in mouse models. Zenidolol can be used as an intraocular pressure-lowering agent in ophthalmic disease research .

HY-14544

Quetiapine 3 Publications Verification ICI204636	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC₅₀ of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pK_is of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-13673A

Goserelin acetate 1 Publications Verification ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-101346

ZD7288 5+ Cited Publications ICI D7288	HCN Channel	Neurological Disease
ZD7288 (ICI D7288) is a selective hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker .

HY-A0261

Pentagastrin 1 Publications Verification ICI-50123	Cholecystokinin Receptor	Metabolic Disease Cancer
Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCK_B) receptor agonist with an EC₅₀ value of 11 nM. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury .

HY-13757AR

Tamoxifen (Standard) 210+ Cited Publications ICI 47699(Standard); (Z)-Tamoxifen(Standard); trans-Tamoxifen (Standard)	Reference Standards Estrogen Receptor/ERR HSP Autophagy Apoptosis	Endocrinology Cancer
Tamoxifen (Standard) is the analytical standard of Tamoxifen (HY-13757A). This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .

HY-106697

Ponalrestat 1 Publications Verification ICI 128436	Aldose Reductase	Metabolic Disease
Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (K_i=7.7 nM) over ALR1 (K_i=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol .

HY-108415

Cloprostenol sodium salt ICI 80996 sodium salt	Prostaglandin Receptor	Endocrinology
Cloprostenol sodium salt (ICI 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent , and is a PGF2α receptor agonist .

HY-13636R

Fulvestrant (Standard) 130+ Cited Publications ICI 182780(Standard); ZD 9238(Standard); ZM 182780 (Standard)	Reference Standards Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant (Standard) is the analytical standard of Fulvestrant. This product is intended for research and analytical applications. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-101432

Fenclozic acid ICI-54450; Acidum fenclozicum; Mialex	COX	Inflammation/Immunology
Fenclozic acid (ICI-54450) is an orally active anti-inflammatory, analgesic, and antipyretic agent. Fenclozic acid exhibits anti-inflammatory activity in Edadjuvant-induced arthritis and Carrageenin-induced oedema in rats. Fenclozic acid can be used for the research of arthritis .

HY-101327A

Xamoterol hemifumarate Corwin hemifumarate; ICI 118587 hemifumarate	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Xamoterol (Corwin; ICI 118587) hemifumarate is an orally active and selective β₁-adrenoceptor partial agonist. Xamoterol hemifumarate acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol hemifumarate can be used for the research of heart failure, postural hypotension, and ischemic heart disease .

HY-13636S

Fulvestrant-d3 ICI 182780-d₃; ZD 9238-d₃; ZM 182780-d₃	Isotope-Labeled Compounds Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-101231

ICI-204448	Opioid Receptor	Neurological Disease
ICI-204448 is a κ-opioid agonist with limited access to the CNS, ICI-204448 can displace the binding of the kappa-opioid ligand 3H-bremazocine from guinea pig cerebellum membranes .

HY-101232

Tiotidine 2 Publications Verification ICI 125211	Histamine Receptor	Cardiovascular Disease
Tiotidine (ICI 125211) is a potent and selective antagonist of histamine H2-receptor (pA₂=7.3-7.8 for guinea-pig right atrium). Tiotidine has low affinity for both the H1 and the H3 receptors .

HY-13636S1

Fulvestrant-d5 ICI 182780-d₅; ZD 9238-d₅; ZM 182780-d₅	Isotope-Labeled Compounds	Others
Fulvestrant-d₅ (ICI 182780-d₅) is a isotope of Fulvestrant (HY-13636) . Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy.

HY-13757AS

Tamoxifen-d5 ICI 47699-d5; (Z)-Tamoxifen-d₅; trans-Tamoxifen-d₅	Isotope-Labeled Compounds Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen-d₅ is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity .

HY-101205

ICI-199441 hydrochloride	Opioid Receptor	Cardiovascular Disease Neurological Disease
ICI-199441 hydrochloride is a potent and selective κ-opioid receptor agonist with analgesic effects. ICI 199441 hydrochloride can improve heart resistance to ischemia/reperfusion .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-B1803A

Tracazolate hydrochloride ICI 136753 hydrochloride	GABA Receptor	Neurological Disease
Tracazolate (ICI 136753) hydrochloride is a potent GABA_A receptor modulator. Tracazolate hydrochloride has selectivity for β3 and potentiates α1β1γ2s (EC₅₀=13.2 μM), α1β3γ2 (EC₅₀=1.5 μM). Tracazolate hydrochloride has the potency (EC₅₀) determined by the nature of the third subunit (γ1-3, δ, ε) within the receptor complex. Tracazolate hydrochloride possesses anxiolytic and anticonvulsant activity .

HY-14544R

Quetiapine (Standard) ICI204636 (Standard)	Reference Standards 5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine (Standard) is the analytical standard of Quetiapine. This product is intended for research and analytical applications. Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC₅₀ of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pK_is of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-13636A

Fulvestrant (S enantiomer) ICI 182780 (S enantiomer); ZD 9238 (S enantiomer); ZM 182780 (S enantiomer)	Drug Isomer Estrogen Receptor/ERR p38 MAPK Apoptosis	Cancer
Fulvestrant (ICI 182780; ZD 9238) S enantiomer is the S-enantiomer of Fulvestrant (HY-13636), a potent estrogen receptor inhibitor. Fulvestrant binds to and blocks the estrogen receptor, promotes its degradation, and thereby inhibits receptor dimerization, nucleocytoplasmic shuttling and transcriptional activity. Fulvestrant effectively blocks estrogen signaling, MAPK pathway activation and ER-regulated protein expression. Fulvestrant induces apoptosis, inhibits the proliferation of breast cancer and prolactinoma cells, and reduces the mineralization level, alkaline phosphatase activity and osteocalcin expression of preosteoblasts. Prenatal exposure to Fulvestrant impairs ovarian follicular development and causes ovarian structural damage. Fulvestrant has been widely used in studies related to breast cancer, prolactinoma and other conditions .

HY-101230

ICI 174864	Opioid Receptor	Neurological Disease
ICI 174864 is a selective and brain-penetrant δ-opioid receptor antagonist with K_e values of 22.0 nM to 30.6 nM at δ-opioid receptor in mouse vas deferens. ICI 174864 selectively blocks biological effects mediated by the δ-opioid receptor agonist DPDPE (HY-P1334) after central administration. ICI 174864 reverses hypotension in rats with endotoxic shock and inhibits acetic acid-induced writhing in mice. ICI 174864 can be used for the research of opioid receptor subtypes, endotoxic hypotension and analgesic pathways .

HY-P3112

ICI 216140	Bombesin Receptor	Neurological Disease
ICI 216140 is a GRP/bombesin receptor 2 antagonist with the IC₅₀ of 2 nM. ICI 216140 can reduce Bombesin (HY-P0195)-stimulated pancreatic amylase secretion and attenuates Bombesin (HY-P0195)-stimulated increases in blood pressure .

HY-15726

ICI 89406	Adrenergic Receptor	Metabolic Disease
ICI 89406 is a selective β1 adrenergic receptor antagonist amenable to labelling with positron emitters, for PET .

HY-13636B

Fulvestrant (R enantiomer) ICI 182780 (R enantiomer); ZD 9238 (R enantiomer); ZM 182780 (R enantiomer)	Estrogen Receptor/ERR	Cancer
Fulvestrant R enantiomer (ICI 182780 R enantiomer) is the R enantiomer of Fulvestrant. Fulvestrant is a potent estrogen receptor antagonist with an IC₅₀ of 9.4 nM.

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-103277A

BIM 23042 TFA 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-106293

ICI-200880	Elastase	Inflammation/Immunology
ICI-200880 is a potent, selective and reversible human neutrophil elastase (HNE) inhibitor. ICI-200880 is promising for research of inflammatory lung diseases related to neutrophil elastase, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) .

HY-137532

7-Hydroxyquetiapine ICI 214227	Drug Metabolite	Neurological Disease
7-Hydroxyquetiapine (ICI 214227) is the major active metabolite of antipsychotic medicine Quetiapine ^{[1] ^.}

HY-123059

(Rac)-Zenidolol hydrochloride (Rac)-ICI-118551 hydrochloride	Adrenergic Receptor	Neurological Disease
(Rac)-ICI-118551 ((Rac)-ICI-118551) hydrochloride is a selective β2-adrenergic receptor antagonist. (Rac)-ICI-118551 hydrochloride can inhibit dendrite ramification of hippocampal neurons in a mouse model of Alzheimer's disease .

HY-101233

ICI 154129 M 154129	Opioid Receptor	Neurological Disease
ICI 154 129 is a delta-opioid receptor antagonist and can be used for seizure research.

HY-17492R

Zafirlukast (Standard) ICI 204219 (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-13673S2

Goserelin-d7 TFA ICI 118630-d7 TFA	Isotope-Labeled Compounds Apoptosis GnRH Receptor	Endocrinology Cancer
Goserelin-d₇ (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-103024

ICI-63197	Environmental Pollutants Phosphodiesterase (PDE)	Neurological Disease
ICI-63197 is a phosphodiesterase 3 (PDE3) and PDE4 inhibitor with K_i values of 9 µM and 10 µM, respectively. ICI-63197 is selectivity against PDE1 and PDE2. ICI-63197 has antidepressant effects .

HY-101235

ICI 185282	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
ICI 185282 is a potent, selective, orally active thromboxane A2 (TXA₂) receptor antagonist. ICI 185282 causes dose-dependent inhibition of U-46619 (HY-108566)-induced platelet aggregation ex-vivo in guinea-pig. ICI 185,282 inhibits bronchospasm induced by U-46619, PGD₂ (HY-101988), PGF_2α (HY-12956), arachidonic acid (HY-109590), LTD₄ and PAF (HY-108635) in vivo. ICI 185282 can be used for bronchial asthma research .

HY-P1619

ICI 186756	Elastase	Others
ICI 186756 is a compound that inhibits the activity of human neutrophil elastase, has a competitive inhibitory effect on the enzyme, can inhibit enzyme-induced lung changes, and can also modulate hamster lung lesions.

HY-101327

Xamoterol Corwin; ICI 118587	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Xamoterol (Corwin; ICI 118587) is an orally active and selective β₁-adrenoceptor partial agonist. Xamoterol acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol can be used for the research of heart failure, postural hypotension, and ischemic heart disease .

HY-13757R

Tamoxifen Citrate (Standard) ICI 46474 (Standard); (Z)-Tamoxifen Citrate (Standard); trans-Tamoxifen Citrate (Standard)	Reference Standards Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen (Citrate) (Standard) is the analytical standard of Tamoxifen (Citrate). This product is intended for research and analytical applications. Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .

HY-13757S

Tamoxifen-d3 hydrochloride ICI 46474-d3 hydrochloride; (Z)-Tamoxifen-d3 hydrochloride; trans-Tamoxifen-d3 hydrochloride	Apoptosis Estrogen Receptor/ERR Autophagy HSP Isotope-Labeled Compounds	Cancer
Tamoxifen-d₃ hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .

HY-P1617

LY 190388	Endogenous Metabolite	Neurological Disease
LY 190388 is a penicillamine-containing enkefa peptide analog with μ receptor agonist activity. LY 190388 showed analgesic effect in inhibiting the writhing response in mice after intracerebroventricular administration. The analgesic effect of LY 190388 is not caused by its δ receptor agonist action, but by its μ receptor agonist activity. When LY 190388 is used together with the δ receptor antagonist ICI 174864, an additive analgesic effect is produced .

HY-101234

ICI 162846	Histamine Receptor	Inflammation/Immunology
ICI 162846 is an orally active antagonist of H₂ receptor. ICI 162846 inhibits acid production accompanied by an increase in the secretion of histamine in chronic duodenal ulcer (CDU) models. ICI 162846 is effective in preventing CDU .

HY-118537

ICI 56780	Parasite	Infection
ICI 56780 is an antimalarial agent, that exhibits etiological prevention and blood schizonticidal activity in rodent malaria models. ICI 56780 develops parasite resistance in P. berghei infected mice .

HY-101205A

ICI-199441	Opioid Receptor	Cardiovascular Disease Neurological Disease
ICI-199441 is a potent and selective κ-opioid receptor agonist with analgesic effects. ICI 199441 can improve heart resistance to ischemia/reperfusion .

HY-101236

ICI 192605	Prostaglandin Receptor	Endocrinology
ICI 192605 is a potent TXA2R (thromboxane A2 receptor) antagonist as cell signaling prostaglandin. ICI 192605 blocks contraction of isolated guinea pig trachea induced by U-46619 .

Cat. No.	Product Name	Target	Research Area

HY-13673A

Goserelin acetate 1 Publications Verification ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-A0261

Pentagastrin 1 Publications Verification ICI-50123	Cholecystokinin Receptor	Metabolic Disease Cancer
Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCK_B) receptor agonist with an EC₅₀ value of 11 nM. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-101230

ICI 174864	Opioid Receptor	Neurological Disease
ICI 174864 is a selective and brain-penetrant δ-opioid receptor antagonist with K_e values of 22.0 nM to 30.6 nM at δ-opioid receptor in mouse vas deferens. ICI 174864 selectively blocks biological effects mediated by the δ-opioid receptor agonist DPDPE (HY-P1334) after central administration. ICI 174864 reverses hypotension in rats with endotoxic shock and inhibits acetic acid-induced writhing in mice. ICI 174864 can be used for the research of opioid receptor subtypes, endotoxic hypotension and analgesic pathways .

HY-P3112

ICI 216140	Bombesin Receptor	Neurological Disease
ICI 216140 is a GRP/bombesin receptor 2 antagonist with the IC₅₀ of 2 nM. ICI 216140 can reduce Bombesin (HY-P0195)-stimulated pancreatic amylase secretion and attenuates Bombesin (HY-P0195)-stimulated increases in blood pressure .

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-103277A

BIM 23042 TFA 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P1617

LY 190388	Endogenous Metabolite	Neurological Disease
LY 190388 is a penicillamine-containing enkefa peptide analog with μ receptor agonist activity. LY 190388 showed analgesic effect in inhibiting the writhing response in mice after intracerebroventricular administration. The analgesic effect of LY 190388 is not caused by its δ receptor agonist action, but by its μ receptor agonist activity. When LY 190388 is used together with the δ receptor antagonist ICI 174864, an additive analgesic effect is produced .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990778

Xirestomig ATG-101	TNF Receptor PD-1/PD-L1	Inflammation/Immunology Cancer
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs) .

Cat. No.	Product Name	Chemical Structure

HY-13636S

Fulvestrant-d3
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-13636S1

Fulvestrant-d5

Fulvestrant-d₅ (ICI 182780-d₅) is a isotope of Fulvestrant (HY-13636) . Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy.

HY-13757AS

Tamoxifen-d5
Tamoxifen-d₅ is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity .

HY-13673S2

Goserelin-d7 TFA
Goserelin-d₇ (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13757S

Tamoxifen-d3 hydrochloride

Tamoxifen-d₃ hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .

HY-13673S1

Goserelin-d7
Goserelin-d₇ (ICI 118630-d₇) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13673S

Goserelin-d10
Goserelin-d₁₀ (ICI 118630-d₁₀) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-14544AS

Quetiapine-d4 hydrochloride

Quetiapine-d₄ (hydrochloride) (ICI204636-d₄ (hydrochloride)) is deuterium labeled Quetiapine. Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC₅₀ of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pK_is of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-17492S3

Zafirlukast-d6
Zafirlukast-d₆ is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S2

Zafirlukast-13C,d6
Zafirlukast- ¹³C,d₆ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S1

Zafirlukast-13C,d3
Zafirlukast- ¹³C,d₃ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-W778408

Tamoxifen-13C6

Tamoxifen- ¹³C₆ (ICI 47699- ¹³C₆) is the ¹³C-labeled Tamoxifen (HY-13757A). Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER transgenic mouse .

HY-13757AS1

Tamoxifen-d3

Tamoxifen-d₃ is the deuterium labeled Tamoxifen . Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .

HY-137532S

7-Hydroxy Quetiapine-d8
7-Hydroxy Quetiapine-d₈ is the deuterium labeled 7-Hydroxyquetiapine. 7-Hydroxyquetiapine (ICI 214227) is the major active metabolite of antipsychotic medicine Quetiapine .

HY-137532S1

7-Hydroxyquetiapine-d4 hemifumarate
7-Hydroxyquetiapine-d₄ (hemifumarate) is deuterium labeled 7-Hydroxyquetiapine. 7-Hydroxyquetiapine (ICI 214227) is the major active metabolite of antipsychotic medicine Quetiapine .

HY-17492S

Zafirlukast-d7
Zafirlukast-d₇ is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects .

Cat. No.	Product Name		Classification

HY-113798

ICI 198583		Alkynes
ICI 198583 is a thymidylate synthase (TS) inhibitor with a K_i value of 10 nM for both mouse and human TS. ICI 198583 serves as a substrate for folylpolyglutamate synthetase (FPGS) with a K_m of 40 μM. ICI 198583 exerts persistent, dose-dependent inhibition on thymidylate synthase flux in mice. ICI 198583 is applicable to relevant research on leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: